Sun Pharma announces US launch of Authorized Generics

Sun Pharmaceutical Industries announced that that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all strengths of:

1. Olmesartan Medoxomil tablets - therapeutic equivalent of Daiichi Sankyo Inc.'s Benicar (olmesartan medoxomil) tablets;

2. Olmesartan Medoxomil-Hydrochlorothiazide tablets - therapeutic equivalent of Daiichi Sankyo Inc.'s Benicar HCT (olmesartan medoxomil-hydrochlorothiazide) tablets;

3. Amlodipine Besylate-Olmesartan Medoxomil tablets - therapeutic equivalent of Daiichi Sankyo Inc.'s Azor (amlodipine and olmesartan medoxomil) tablets; and

4. Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets - therapeutic equivalent of Daiichi Sankyo Inc.'s Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets.

The launch is pursuant to a distribution and supply agreement between Sun Pharma's wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period.

 

Benicar, Benicar HCT, Azor and Tribenzor recorded US sales of approximately US$ 2.5 billion for the 12 months ending 31 August 2016, as per IMS Health.

Powered by Capital Market - Live News